A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).

被引：1

作者：

Attard, Gerhardt

Merseburger, Axel S.

Sternberg, Cora N.

Cerbone, Linda

Recine, Federica

Jones, Robert J.

Feyerabend, Susan

Berruti, Alfredo

Joniau, Steven

Schatteman, Peter

Geczi, Lajos

Tenke, Peter

Werbrouck, Patrick

Lefresne, Florence

Shelby, Florence Nave

Lahaye, Marjolein

Pick, Corinna

Tombal, Bertrand F.

机构：

[1] Inst Canc Res, London SW3 6JB, England

[2] Royal Marsden Hosp, London SW3 6JJ, England

[3] Med Univ Lubeck, Dept Urol, D-23538 Lubeck, Germany

[4] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy

[5] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[6] Studienpraxis Urol, Nurtingen, Germany

[7] Univ Brescia, Med Oncol, Spedali Civili Hosp, Brescia, Italy

[8] Univ Hosp Leuven, Leuven, Belgium

[9] Onze Lieve Vrouw Hosp, Aalst, Belgium

[10] Natl Inst Oncol, Chemotherapy & Clin Pharmacol Dept C, Budapest, Hungary

[11] Jahn Ferenc Del Pesti Korhaz, Dept Urol, Budapest, Hungary

[12] AZ Groeninge, Kortrijk, Belgium

[13] Janssen Cilag, Paris, France

[14] Janssen Cilag, Tilburg, Netherlands

[15] Janssen Cilag, Neuss, Germany

[16] Catholic Univ Louvain, Inst Rech Expt & Clin, B-1200 Brussels, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期

关键词：

D O I：

10.1200/jco.2016.34.2_suppl.261

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

261

引用

页数：2